Comparison
Resveratrol vs. Pterostilbene
Resveratrol or pterostilbene – is the relative the better resveratrol?
The short answer
Both are stilbenes, and for both the sirtuin story comes from cell and animal studies. Resveratrol is well studied in humans, but no benefit has been shown: an umbrella review of ten meta-analyses found no significant effects apart from LDL reduction, and in a training study the rise in VO2max was 45 percent greater on placebo. Pterostilbene was absorbed at about 80 percent in rats, resveratrol at about 20 percent. In humans there is one randomized trial with 80 adults: blood pressure fell on the high dose, while LDL cholesterol rose. There is no direct comparison in humans. High-purity pterostilbene is an unauthorized novel food in the EU.
The numbers side by side
| Axis | Resveratrol | Pterostilbene | Difference |
|---|---|---|---|
| Human evidenceHow much and how good the data in humans are | 4 | 4 | even |
| MechanismHow well the chain of action is understood | 5 | 4 | Resveratrol better studied |
| Safety dataHow well safety has been studied – not how safe it is | 7 | 4 | Resveratrol better studied |
| Hype gap10 means: the advertising stays level with the data | 1 | 2 | Pterostilbene closer to the data |
| Track record of useHow much documented use in humans exists – does not measure whether it works | 7 | 4 | Resveratrol in use longer |
| Rating | Studied – no benefit shown · Thin human evidence | ||
“Track record of use” measures how long and how widely something has been used in humans – not whether it works. The BK-Score is a subjective assessment by Biohacking Kompakt based on published scoring rules (German). It is not a scientific rating, not the consensus of a professional society and not a medical recommendation.
Why these numbers
Resveratrol
The cautionary tale of the longevity scene: twenty years of headlines, a billion-dollar deal – and to this day no robust proof of efficacy in humans, plus doubts about key sirtuin studies. Resveratrol has certainly been studied in humans: for type 2 diabetes alone there are ten meta-analyses, and an umbrella review of them found no significant effects apart from LDL reduction (Ghalichi 2026). Bioavailability is low. The largest hype gap in the entire collection.
Pterostilbene
Evidence 4 rather than 2, because one randomized, double-blind, placebo-controlled trial with 80 adults over 6 to 8 weeks measures surrogate markers (Riche 2014: LDL +17.1 mg/dl, blood pressure −7.8/−7.3 mmHg at the high dose) and small studies add to this (Otsuka 2025: 30 men, 12 weeks, microRNA; Senguttuvan 2025: 44 patients, primary endpoint Ki-67 without difference); clinical endpoints are missing, and the larger studies (Dellinger 2017, 120 older adults; Dellinger 2023, 111 patients with fatty liver, main endpoint missed) test only the combination with nicotinamide riboside. Mechanism stays at 4: sirtuin and AMPK activation from cell and animal studies, the bioavailability advantage (about 80% versus 20%) only in rats (Kapetanovic 2011). Safety 4 rather than 3: controlled short-term data up to 12 weeks without abnormalities in liver, kidney and glucose (Riche 2013), but LDL increase, platelet inhibition in vitro (Huang 2021) and CYP2C9 inhibition in liver microsomes (Albassam 2021). Direction mixed rather than open, because blood pressure fell but LDL rose – the opposite of the cardiovascular marketing promise. An unauthorized novel food in the EU.
Frequently asked questions
Is pterostilbene better than resveratrol?
That has not been shown. The advantage pterostilbene is marketed with is absorption: in rats, oral bioavailability was about 80 percent versus about 20 percent for resveratrol (Kapetanovic 2011). Whether the same holds in humans, and whether it leads to a better effect, has not been studied. There are no direct comparison studies in humans; the individual studies can only be laid side by side.
Do resveratrol and pterostilbene activate sirtuins?
In cell studies, yes; in humans this is proven for neither. For resveratrol, SIRT1, AMPK and PPARGC1A remained unchanged in two randomized trials, while a small study in eleven overweight men found more SIRT1 protein in muscle (Timmers 2011). For pterostilbene, no human study has directly measured sirtuin or AMPK activation. Studies with lifespan or clinical endpoints are lacking for both.
What do resveratrol and pterostilbene do to blood pressure and cholesterol?
Across ten meta-analyses in type 2 diabetes, resveratrol showed no consistent effect on blood lipids; only a single analysis found an LDL reduction. In older inactive men, it cancelled out the positive training effects on blood pressure and blood lipids. With pterostilbene alone, blood pressure fell by 7.8/7.3 mmHg on the high dose in a study of 80 adults, while LDL cholesterol rose by 17.1 milligrams per decilitre, though not in combination with grape extract.
What should you know about the safety of resveratrol and pterostilbene?
The resveratrol studies reviewed report no adverse effects, but the blunted training effect is documented; caution with blood thinners and an oestrogenic effect are also mentioned. Pterostilbene was well tolerated in the short term, but long-term data are missing. In the test tube it inhibited platelets and the enzyme CYP2C9, so caution is advised with anticoagulants. High-purity pterostilbene is an unauthorized novel food in the EU.
See all ratings in the ranking (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in a doctor's hands.